SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp after-hours drop drew attention as traders linked the move to the FAAs nationwide ground stop after communications problems, while speculation about a cyberattack or AI involvement remained unverified. The discussion also reflected wider pressure on tech and AI stocks tied to uncertainty around Nvidia, with traders divided between seeing the selloff as an overreaction and expecting further weakness.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summits FDA review of ivonescimab for EGFR-mutated lung cancer is driving a binary-outcome debate over approval versus a possible rejection or request for more evidence. Bulls point to strong progression-free-survival results and encouraging survival trends, while bears focus on the FDAs stated need for statistically significant overall-survival evidence; recent weakness has also prompted speculation about a negative outcome, though traders say price action alone is not proof.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

The upcoming Phase 3 REGAL trial readout for SELLASs AML treatment GPS dominates discussion, with traders focused on the binary clinical catalyst. Bulls anticipate strong results, while skeptics cite the stocks sharp volatility and warn of failure risk or a sell-the-news reaction; claims of short-term manipulation remain speculation.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivians volatile, weak share performance is driving debate, with traders blaming heavy short-selling and persistent selling pressure while bulls point to improving deliveries, the R2 ramp, and upcoming autonomy developments. Sentiment remains split between concern over cash burn and execution and hopes that the companys growth initiatives can improve its outlook.

American Airlines Group, Inc. is a holding company, which engages in the operation of a network carrier through its principal wholly owned mainline operating subsidiary, American. The firm offers air transportation for passengers and cargo. It operates through the following geographical segments: Domestic, Latin America, Atlantic, and Pacific. The company was founded on December 9, 2013, and is headquartered in Fort Worth, TX.

American Airlines Group Inc

Reports of an FAA nationwide ground stop tied to air-traffic-control communications problems are drawing attention to AAL, with traders discussing possible departure delays and rerouting. Some characterize the disruption as brief, while speculation about its cause remains unverified.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Reported takeover discussions involving Silver Lake and Saudi Arabias PIF are driving speculation, though no deal is confirmed; traders disagree over whether a potential offer would undervalue Unity. The interest is reinforced by strong quarterly results and the companys first GAAP-profitable quarter, with bullish call activity and breakout chatter alongside skepticism about the rally.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius selloff is being tied to its earnings outlook and delays in activating third-party data-center capacity, which push expected revenue into a later period and have prompted analyst price-target cuts. Traders are divided between viewing the execution and heavy-capex concerns as a reason for further downside and treating the drop as an overreaction, with broader weakness in AI and neocloud stocks adding pressure.

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novos stronger-than-expected quarterly results and raised full-year outlook, driven largely by demand for its Wegovy pill, have fueled renewed buying interest. Traders are debating whether the oral drugs momentum can support a sustained recovery amid Lilly competition and concerns about Novos execution.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Jensen Huangs abrupt departure is driving debate over Nvidias leadership transition, with traders speculating about his return and possible successors while others worry about leadership uncertainty and scrutiny of chip exports to China. Bulls argue Nvidias business remains strong and point to earnings, while bears see unresolved risks weighing on confidence.

HawKeye 360, Inc. engages in the provision of defense technology. It offers spectrum monitoring, maritime intelligence, air defence radar monitoring, GNSS interference detection, and communications mapping. Its costumers include a wide range of commercial, government and international entities. The company was founded by Charles T. Clancy, Robert G. McGwier, Chris DeMay and John Serafini in 2015 and is headquartered in Herndon, VA.

HawkEye 360 Inc.

HAWK is drawing attention after reporting record third-quarter revenue and raising its full-year outlook, with traders also highlighting international growth, contract demand, and plans for lower-cost satellites. The community reaction is broadly bullish on the results and rally, though claims of institutional accumulation and further upside remain speculative.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioMarin to Participate in Upcoming Investor Conferences

BioMarin to Participate in Upcoming Investor Conferences BioMarin to Participate in Upcoming Investor ConferencesPR NewswireSAN RAFAEL, Calif., Nov. 4, 2026 Stifel Healthcare Conference, November 11 at 3:20 pm ESTUBS Global Biopharma Conference, November 16 at 9:20 am GMTJefferies Global Healthcare...

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for BioMarin (BMRN) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

BioMarin (BMRN) delivered earnings and revenue surprises of +355.56% and -0.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Reports Third Quarter 2026 Financial and Operating Results

BioMarin Reports Third Quarter 2026 Financial and Operating Results BioMarin Reports Third Quarter 2026 Financial and Operating ResultsPR NewswireSAN RAFAEL, Calif., Nov. 2, 2026 Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic...

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking 

Equity

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 


BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease

BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi Pharm for Investigational Next-Generation Enzyme Replacement Therapy, Adding a Second Potential Treatment for Fabry Disease BioMarin Enters Into Exclusive Worldwide License Agreement With GC Biopharma and Hanmi...

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET

BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ET BioMarin to Host Third Quarter 2026 Financial Results Conference Call and Webcast on Monday, November 2, 2026, at 4:30pm ETPR NewswireSAN RAFAEL, Calif., Oct. 26, 2026 SAN...

Earnings Preview: Bristol Myers Squibb (BMY) Q3 Earnings Expected to Decline

Bristol Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

BioMarin Pharmaceutical (BMRN) Earnings Expected to Grow: Should You Buy?

BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

• Reported GAAP EPS of $0.23 up 91.67% YoY
• Reported revenue of $1.02B up 32.02% YoY
• BioMarin updated FY2026 guidance to total revenues of $3.8B, Metabolic Conditions $2.68B, VOXZOGO $975M, and Non-GAAP Diluted EPS $2.80 to $3.10.

BioMarin's updated FY2026 revenue and EPS ranges are below previous guidance; GAAP losses included acquisition costs, while revenue guidance reflects order-timing uncertainty tied to a single international customer.

BioMarin's Metabolic Conditions revenue grew 44% Y/Y; VOXZOGO received a May 30, 2027 HCH PDUFA date and EMA validation, while pipeline additions include an investigational Fabry therapy.

BioMarin Pharmaceutical, Inc. is a global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. The company has a proven track record of innovation, with nine commercial therapies and a strong clinical and preclinical pipeline. Using a distinctive approach to drug discovery and development, BioMarin seeks to unleash the full potential of genetic science by pursuing category-defining medicines that have a profound impact on patients. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997 and is headquartered in San Rafael, CA.

Biomarin Pharmaceutical Inc. - Registered Shares

Bearish Sentiment

<ul class="summary-bullets"><li>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A.&nbsp;</li><li>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale.</li><li>The week marked an extension of a quieter stretch in biotech dealmaking after larger deals in the first half of 2026.</li></ul><p>U.S.-listed drugmakers continued to prefer asset licensing and bankruptcy purchases of drug candidates this week rather than large full-company acquisitions, marking a quieter stretch compared with earlier in 2026, when multi-billion-dollar buyouts of U.S. biotechs dominated.</p><p>This week, rare-disease enzyme therapies and late-stage neuroscience assets drew the most capital as BioMarin and Teva sought to strengthen their positions in certain clinical areas.</p><h2 class="st-heading-2">BioMarin Licenses Long-Acting Fabry Therapy</h2><p>BioMarin (BMRN) signed an exclusive worldwide license earlier this week with South Korea’s GC Biopharma and Hanmi Pharm for HM15421/GC1134A, an investigational long-acting enzyme replacement therapy for Fabry disease, a rare disorder that causes a fatty substance to build up inside cells and blood vessels.</p><p>BioMarin is paying $70 million upfront. The Korean partners are jointly eligible for up to $405 million in further milestones plus tiered royalties. The candidate is in an early-stage trial and is designed for subcutaneous dosing. BioMarin will lead subsequent global development and commercialization outside Korea.</p><p>The licensing deal reflects BioMarin’s efforts to build a pipeline aimed at Fabry, after its acquisition of Amicus Therapeutics was completed earlier this year. The previous deal brought Amicus’s Galafold, approved for Fabry disease, under BioMarin’s fold.</p><p><a class="mention" data-mention="$BMRN" data-symbol-id="BMRN" href="https://stocktwits.com/symbol/BMRN" target="_blank">BMRN stock</a> gained about 5% this week.</p><h2 class="st-heading-2">Teva Acquires BioXcel Neuroscience Assets</h2><p>Teva (TEVA) completed the acquisition of neuroscience assets from BioXcel Therapeutics through a court-supervised bankruptcy sale. The deal, announced earlier this week, includes worldwide rights to BXCL501, an investigational therapy under FDA review for potential at-home treatment of agitation associated with schizophrenia or bipolar disorder, and the approved hospital product IGALMI. Teva paid $57.5 million upfront and could owe up to $67.5 million in contingent payments tied to regulatory timing and sales milestones.</p><p>The purchase supports Teva’s pivot toward innovative neuroscience assets. Earlier this year, the company also acquired Emalex Biosciences for $700 million upfront to gain its neuroscience candidate ecopipam for the treatment of Tourette syndrome.</p><p>TEVA stock added about 7% this week.</p><h2 class="st-heading-2">The Shift In Dealmaking Approach</h2><p>Earlier in 2026, U.S.-listed buyers deployed substantial capital to fully acquire other U.S. biotechs. Major deals that moved markets included Vertex’s <a href="https://stocktwits.com/news-articles/markets/equity/crnx-stock-soars-nearly-100-percent-on-vertex-10-billion-acquisition/cZmlGWWR7mT">acquisition</a> of Crinetics, AbbVie’s purchase of Apogee, Gilead’s buyout of Arcellx, and others that together pushed total U.S. biotech <a href="https://stocktwits.com/news-articles/markets/equity/gilead-merck-eli-lilly-lead-106-billion-takeover-wave-in-2026/cZ0FblYRezX">merger and acquisition</a> value well above prior-year levels by the end of the third quarter. Capital also flowed into large licensing packages, particularly for China-originated assets showing potential in immune-system-mediated diseases, cancer, or obesity.</p><p>On Stocktwits, retail sentiment around BMRN was 'neutral' at the time of writing, while sentiment around TEVA was 'neutral.'&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/stocktwits-zero-to-sixty-rivian-beats-q3-estimates-on-r2-strength-and-raises-guidance-tesla-expands-robotaxi-fleet-and-ford-advances-low-cost-ev-plans/cZUKK8sR9cB">Stocktwits Zero To Sixty: Rivian Raises Delivery Guidance On R2 Demand, Tesla Expands Robotaxi Fleet, And Ford Advances Low-Cost EV Plans</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Assortment of colorful tablets, capsules, and softgel supplements arranged in a clean repeating pattern against a minimal background. Source: Getty Images

U.S.-listed biotech buyers continued to favor asset deals over multi-billion-dollar company takeovers this week. 

Stocktwits Biotech Dealmaker: BioMarin’s Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking

Teva- Pharmaceutical Industries Ltd. - ADR

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

BMRN News